Overview

A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet

Status:
Completed

Trial end date:
2006-11-28

Target enrollment:

Participant gender:

Summary

This is a Phase IV randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SC efalizumab in adult patients (18 years of age and older) with chronic moderate to severe plaque psoriasis involving the hands and/or feet who have had no previous exposure to efalizumab. The study will consist of a screening period, a treatment period, and an observation period.

Phase:

Phase 4

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Antibodies, Monoclonal